Burden of disease progression in patients with multiple myeloma in the US

Abstract

Effects of disease progression on healthcare resource utilization (HRU) and costs among multiple myeloma (MM) patients with ≥1 line of therapy (LOT) and without receipt of stem cell transplant were estimated using large US claims database. Disease progression was defined as advancement to the next LOT, bone metastasis, hypercalcemia, soft tissue plasmacytoma, skeletal related events, acute kidney failure, or death within 12 months of LOT initiation. Annual HRU and costs in the first four LOTs were compared for patients with versus without progression using inverse probability of treatment weighting to adjust for differences between groups in baseline characteristics. In all LOTs, mean annual hospitalizations and healthcare costs were greater for patients with versus without progression. Total incremental annual costs among patients with versus without progression in 1LOT to 4LOT were $25,920, $30,632, $47,320, and $19,769, respectively. For MM patients receiving drug therapy, the economic burden of disease progression is substantial.

Keywords:

• Multiple myeloma
• disease progression
• healthcare costs
• retrospective study

Disclosure statement

Sumeet Panjabi and Emre Yucel are employees of Amgen, Inc. Rafael Fonseca is a consultant for Amgen, AbbVie, Bayer, BMS, Celgene, Jansen, Juno, Kite, Pharmacyclics, Sanofi, and Takeda, and is on the Scientific Advisory Board of Adaptive Biotechnologies. May Hagiwara and Thomas Delea received research funding from Amgen, Celgene, EMD Serono, Jazz, Merck, Novartis, Pfizer, Sanofi, Seattle Genetics, and Takeda.

Additional information

Funding

Funding for this study was provided to Policy Analysis Inc. by Amgen Inc.